Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

被引:140
|
作者
Borgmann-Staudt, A. [1 ]
Rendtorff, R.
Reinmuth, S.
Hohmann, C. [2 ]
Keil, T. [2 ]
Schuster, F. R. [3 ]
Holter, W. [4 ]
Ehlert, K. [5 ]
Keslova, P. [6 ]
Lawitschka, A. [7 ]
Jarisch, A. [8 ]
Strauss, G.
机构
[1] Charite, Campus Virchow Klinikum, Klin Padiatrie MS Onkol Hamatol, Dept Paediat Oncol & Haematol, D-13353 Berlin, Germany
[2] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany
[3] Univ Dusseldorf, Clin Pediat Oncol Hematol & Clin Immunol, Fac Med, Ctr Child & Adolescent Hlth, D-40225 Dusseldorf, Germany
[4] Erlangen Univ Hosp, Dept Paediat, Dept Immunol & Oncol, Erlangen, Germany
[5] Univ Childrens Hosp Muenster, Dept Paediat Haematol & Oncol, Munster, Germany
[6] Motol Univ Hosp, Dept Paediat Haematol & Oncol, Prague, Czech Republic
[7] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria
[8] Univ Frankfurt Hosp, Dept Haematol, Frankfurt, Germany
关键词
allogeneic haematopoietic stem cell transplantation; cytotoxic therapy; pregnancy outcome; fertility; childhood; BONE-MARROW-TRANSPLANTATION; INDUCED OVARIAN FAILURE; CHEMOTHERAPY; RADIOTHERAPY; RADIATION; HORMONE; WOMEN;
D O I
10.1038/bmt.2011.78
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of HSCT and 19 (range 12-35) years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age >= 13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens. Bone Marrow Transplantation (2012) 47, 271-276; doi:10.1038/bmt.2011.78; published online 11 April 2011
引用
收藏
页码:271 / 276
页数:6
相关论文
共 50 条
  • [21] CMV resistance in patients after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Kouba, M.
    Boutolleau, D.
    Pliskova, L.
    Vejrazkova, E.
    Keslova, P.
    Sedlacek, P.
    Cetkovsky, P.
    JOURNAL OF CLINICAL VIROLOGY, 2015, 70 : S125 - S126
  • [22] Allogeneic Haematopoietic Stem Cell Transplantation - An Overview
    Holtick, U.
    Chemnitz, J. M.
    Hallek, M.
    Scheid, C.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2015, 232 (05) : 641 - 646
  • [23] Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation
    I Hilgendorf
    J Casper
    L Sviland
    F Prall
    C Junghanss
    M Freund
    D Wolff
    Bone Marrow Transplantation, 2007, 39 : 245 - 246
  • [24] The thymus in allogeneic haematopoietic stem cell transplantation
    Choufi, Bachra
    Lassoued, Kaiss
    HEMATOLOGIE, 2012, 18 (05): : 272 - 282
  • [25] Cardiac biomarkers during and after allogeneic haematopoietic stem cell transplantation
    Roziakova, L.
    Bojtarova, E.
    Mistrik, M.
    Demeckova, E.
    Mladosievicova, B.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S170 - S170
  • [26] Quality of life in patients after allogeneic haematopoietic stem cell transplantation
    Stancheva, N.
    Semenova, E.
    Zubarovskay, N.
    Paina, O.
    Vasilieva, Y.
    Alyansky, A.
    Bagge, D.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S88 - S88
  • [27] Rehabilitation after Allogeneic Haematopoietic Stem Cell Transplantation: A Special Challenge
    Bertz, Hartmut
    CANCERS, 2021, 13 (24)
  • [28] T-CELL RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
    Ligeiro, Dario
    Abecasis, Manuel
    Lima, Alice
    Miranda, Nuno
    Ferreira, Isabelina
    Teixeira, Gilda
    Trindade, Helder
    TISSUE ANTIGENS, 2013, 81 (05): : 302 - 302
  • [29] Efficacy of darbopoietin alfa after allogeneic haematopoietic stem cell transplantation
    Picardi, A
    Spagnoli, A
    Tendas, A
    Mirabile, M
    Cudillo, L
    Dentamaro, T
    Suppo, G
    Amadori, S
    de Fabritiis, P
    BONE MARROW TRANSPLANTATION, 2005, 35 : S103 - S103
  • [30] CMV resistance in patients after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Kouba, M.
    Boutolleau, D.
    Pliskova, L.
    Vejrazkova, E.
    Keslova, P.
    Sedlacek, P.
    Cetkovsky, P.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S78 - S78